SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics, Inc., a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that interim results of its Phase 3 study clinical trial for MDR-101 cell therapy will be presented as a Rapid Fire Oral Presentation by lead Principal Investigator Dr. Dixon Kaufman of the University of Wisconsin at the American Transplant Congress (ATC) on June 7, 2021.
Medeor’s Phase 3 tolerance study is a randomized, multi-center study evaluating the establishment of functional immune tolerance in MDR-101 recipients of HLA-matched living donor kidney transplants. This is the first randomized, multi-center pivotal study specifically designed to eliminate the use of immunosuppressive anti-rejection drugs following transplant.
Currently, patients who receive a kidney transplant are dependent upon a lifelong regimen of immunosuppressive drugs – often up to 25 pills a day – that are associated with a litany of side effects and toxicities, and limited efficacy which ultimately impact graft and patient survival, such that 30% to 50% of all kidney transplants fail by 10 years. MDR-101 is a single-dose cellular therapy derived from a living kidney donor’s blood. The therapy is designed to establish mixed chimerism - the co-existence of both recipient-derived and donor-derived blood and immune cells - to allow HLA-matched living donor kidney transplant recipients to discontinue immunosuppressive drug use while preserving long-term graft function and survival.
Details of the oral presentation are as follows:
Presentation Title: MDR-101-MLK-MERCURY Kidney Transplant Tolerance Study Update
Session Name: Biomarkers, Immune Assessment and Clinical Outcomes - III
Abstract number: 223
Presentation Time: 5:00 pm – 5:05 pm ET
Medeor Therapeutics is also hosting a virtual symposium, “Reprogramming the Immune System to Preserve Kidney Function Post Transplant” on Wednesday, June 17, 2021 at 7–8 pm ET to discuss the latest advances in organ transplant cell therapy to induce donor-specific immune tolerance and avoid transplant kidney rejection. The symposium will include a KOL roundtable featuring:
- Stephan Busque, M.D., Stanford University Medical Center
- Dixon Kaufman, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health
- Sanjeev Akkina, M.D., Loyola University Medical Center
- Daniel Brennan, M.D., Medeor Therapeutics (moderator)
In addition, Medeor Therapeutics Chief Medical Officer Dr. Daniel Brennan will provide a company overview and update on future plans.
To register for the symposium, please visit https://www.eventbrite.com/e/redefining-organ-transplants-virtual-symposium-june-17-2021-tickets-155809822373.
MDR-101 is a single dose cellular therapy manufactured from a living kidney donor’s blood and peripheral stem cells. MDR-101 is intended to induce donor-specific immune tolerance in order to avert transplant kidney rejection and thereby preserve transplant kidney function and survival without the cumulative and serious side effects associated with immunosuppressive drugs. Medeor’s Phase 3 trial is supported in part by a grant from the California Institute for Regenerative Medicine. For more information on Medeor’s Phase 3 trial, please visit https://clinicaltrials.gov.
About Medeor Therapeutics, Inc.
Medeor Therapeutics is working to improve the lives of transplant patients by eliminating or minimizing the need for a life-long regimen of immunosuppressive medications and their potential life-threatening side effects. Medeor’s Phase 3 clinical study is demonstrating the significant opportunities of this one-time therapy. For more information, visit www.medeortx.com.